Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

1 Aug 2005 07:01

Angle PLC01 August 2005 For Immediate Release 1 August 2005 ANGLE plc ("ANGLE" or the "Company") Formation of Executive Management Board and Board Change ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryannounces the formation of an Executive Management Board which will reportdirectly to the ANGLE plc Board. In recognition of the Company's recent successes, rapid expansion and futureprospects across the United Kingdom, United States and the Middle East, ANGLEhas strengthened its management structure and promoted Stephen Bates, currentlyDirector of UK Ventures, to UK Chief Executive. Responsibility for HR,marketing, IT and operations will now be devolved from the Board to regionalchief executives ensuring full responsibility for all activities in theirrespective regions. With immediate effect, the Executive Management Board will consist of Group CEO,Andrew Newland and Finance Director, Ian Griffiths, together with: Stephen Bates, UK Chief Executive Stephen Bates has an MA in engineering, and an MBA. Following 10 years withinthe product development industry his career has taken him to ScientificGenerics, Arthur D. Little and Marks & Spencer prior to joining ANGLE in 2004.Dr Gary Evans, US Chief Executive Gary Evans has a BSc in Chemistry, a PhD in Physical Chemistry, and a Diploma inManagement Science and was Visiting Professor in Innovation Management at theRobert Gordon University, Aberdeen. Following a career with Cambridge LifeSciences and then Scottish Enterprise, Dr. Evans joined ANGLE in 1997. Dr Eulian Roberts, Middle East Chief Executive Eulian Roberts has a BSc in Microbiology, a PhD in Molecular Biology and an MBA.He gained three years' post-doctoral experience and then joined ScottishEnterprise. He then became chief executive of the Stirling University InnovationPark, managing director of Coventry University Enterprises Limited and adirector of the UK Science Park Association. Dr Roberts joined ANGLE in 1998. As a result of these changes, Dawson Buck will be stepping down from hisposition as Deputy Chief Executive, with immediate effect. He remains a directorof ANGLE's venture companies, Corpora plc and Provexis plc. Commenting on the new organisational structure, Group CEO, Andrew Newland, said: "The formation of an Executive Management Board establishes a clear managementstructure and accountability by region which will improve the efficiency andintegration of our Consulting & Management and Ventures operations, streamlineoverheads and facilitate our continuing rapid growth. The new management structure gives us the platform we need to grow the businesssubstantially. I am delighted to have such high calibre individuals within theExecutive Management Board. I would also like to put on record my thanks to Dawson Buck for all hiscontributions to the ANGLE Board over the last five years." For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44 (0)1483 295830 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.